Medincell Continues to Strengthen and Renew its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg

Source Summary

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced that its Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at the Company's Annual General Meeting on September 30, 2026. A highly experienced international life sciences executive, Dr. Svanberg would bring deep expertise in global pharmaceutical development, governance, executive compensation and global health as Medincell advances its next phase of growth.